Minority Recruitment in the Prostate Cancer Prevention Trial

作者: Carol Mcmillen Moinpour , Jonnae O Atkinson , Sarah Moody Thomas , Sandra Millon Underwood , Carolyn Harvey

DOI: 10.1016/S1047-2797(00)00185-X

关键词:

摘要: Abstract PURPOSE: African American men have a higher prostate cancer risk profile than that of other in the United States. The purpose this manuscript is to summarize challenges associated with enrolling and randomizing minority participants Prostate Cancer Prevention Trial (PCPT). METHODS: PCPT randomized trial finasteride versus placebo for preventing healthy age 55 years older; it coordinated by Southwest Oncology Group. describes demographic lifestyle characteristics sample (18,882 men) four racial ethnic groups (Caucasian, American, Hispanic, other). comprised 4% total compared our goal 8%. Minority recruitment was emphasized through Study Manual training occurred at activation. Supplemental activities were initiated year after study activation continued end accrual period. as follows: presentations seminars (held during twice yearly Group meetings); distribution additional materials; engagement consultants recruitment; production Recruitment Manual; small pilot involving outreach recruiters five sites. RESULTS: helpful implementing project suggesting reviewing materials recruitment. five-site did not increase either enrollment or randomization minorities (with possible exception one site). CONCLUSIONS: We suggest long-term perspective required successful clinical trials. Likewise, extensive efforts must be ready implement

参考文章(21)
V T DeVita, S Hellman, S A Rosenberg, Important advances in oncology Anti-Cancer Drugs. ,vol. 2, pp. 419- ,(1991) , 10.1097/00001813-199108000-00014
G. M. Swanson, A. J. Ward, Recruiting Minorities Into Clinical Trials Toward a Participant-Friendly System Journal of the National Cancer Institute. ,vol. 87, pp. 1747- 1759 ,(1995) , 10.1093/JNCI/87.23.1747
Charles A. Coltman, Jr., Ian M. Thompson, Jr., Polly Feigl, Prostate Cancer Prevention Trial (PCPT) Update European Urology. ,vol. 35, pp. 544- 547 ,(1999) , 10.1159/000019895
Laura C. Lovato, Kristin Hill, Stephanie Hertert, Donald B. Hunninghake, Jeffrey L. Probstfield, Recruitment for controlled clinical trials: Literature summary and annotated bibliography Controlled Clinical Trials. ,vol. 18, pp. 328- 352 ,(1997) , 10.1016/S0197-2456(96)00236-X
Electra D. Paskett, Cecilia DeGraffinreid, Cathy M. Tatum, Susan E. Margitić, The recruitment of African-Americans to cancer prevention and control studies. Preventive Medicine. ,vol. 25, pp. 547- 553 ,(1996) , 10.1006/PMED.1996.0088
GLENN J. GORMLEY, OTIS BRAWLEY, IAN THOMPSON, The Potential Application of Finasteride for Chemoprevention of Prostate Cancer Annals of the New York Academy of Sciences. ,vol. 768, pp. 163- 169 ,(1995) , 10.1111/J.1749-6632.1995.TB12119.X
Craig K. Svensson, Representation of American Blacks in Clinical Trials of New Drugs JAMA: The Journal of the American Medical Association. ,vol. 261, pp. 263- 265 ,(1989) , 10.1001/JAMA.1989.03420020117041
Richard Day, Patricia A. Ganz, Joseph P. Costantino, Walter M. Cronin, D. Lawrence Wickerham, Bernard Fisher, Health-Related Quality of Life and Tamoxifen in Breast Cancer Prevention: A Report From the National Surgical Adjuvant Breast and Bowel Project P-1 Study Journal of Clinical Oncology. ,vol. 17, pp. 2659- 2659 ,(1999) , 10.1200/JCO.1999.17.9.2659
Arnold D. Kaluzny, Linda M. Lacey, Richard Warnecke, Joseph P. Morrissey, Edward J. Sondik, Leslie Ford, Accrual of Patients to Randomized Clinical Trials: Factors Affecting Cancer Prevention and Control Research International Journal of Technology Assessment in Health Care. ,vol. 10, pp. 506- 516 ,(1994) , 10.1017/S0266462300006723